-

Kaskela Law LLC Announces Shareholder Investigation of Trean Insurance Group (NASDAQ: TIG) and Encourages TIG Investors to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Shareholder protection law firm Kaskela Law LLC announces that it is investigating Trean Insurance Group, Inc. (NASDAQ: TIG) (“Trean” or the “Company”) on behalf of the Company’s investors.

On December 16, 2022, Trean announced that it would be acquired by affiliates of Altaris, LLC (“Altaris”) at a price of $6.15 per share – a price that is 35% lower than Trean’s 52-week high value of $9.47 per share. Following the closing of the proposed transaction, Trean’s investors will be cashed out of their investment position and the Company’s shares will no longer be publicly traded.

The investigation seeks to determine whether Trean’s officers and directors failed to maximize the buyout price for the company’s stockholders, or otherwise breached their fiduciary duties to Trean stockholders in agreeing to sell the company to Altaris at $6.15 per share.

Trean shareholders are encouraged to contact Kaskela Law LLC (Adrienne Bell, Esq.) at (484) 229 – 0750, or by email (abell@kaskelalaw.com) or online at https://kaskelalaw.com/cases/trean/, for additional information about this investigation and their legal rights and options.

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

This notice may constitute attorney advertising in certain jurisdictions.

Contacts

D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
(888) 715 – 1740
www.kaskelalaw.com

Kaskela Law LLC

NASDAQ:TIG

Release Versions

Contacts

D. Seamus Kaskela, Esq.
Adrienne Bell, Esq.
KASKELA LAW LLC
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
(888) 715 – 1740
www.kaskelalaw.com

More News From Kaskela Law LLC

Kaskela Law LLC Announces Investigation into Fairness of $9.50 Per Share Global Business Travel Group (GBTG) Stockholder Buyout; Affected Investors are Encouraged to Contact the Firm to Protect Their Investment and Legal Rights

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Kaskela Law is investigating the fairness of the recently announced buyout of Global Business Travel Group, Inc. (NYSE: GBTG) (“GBTG”) shareholders to determine whether the transaction as structured provides investors with a sufficient price for their GBTG shares. Click here to register for additional information about this investigation: https://kaskelalaw.com/case/global-business-travel-group/ On May 4, 2026, GBTG announced that it had agreed to go privat...

Kaskela Law LLC Announces Shareholder Investigation of Playtika Holding Corp. and Encourages Investors with Losses to Contact the Firm – PLTK

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Shareholder litigation law firm Kaskela Law is investigating Playtika Holding Corp. (NASDAQ: PLTK) (“Playtika”) on behalf of the company’s investors. Click here to register for additional information about this investigation: https://kaskelalaw.com/case/playtika-holding/ Since July 2025, shares of Playtika’s common stock have declined in value from a trading price of over $4.50 per share to a current price of less than $3.50 per share, a decline of over 22%...

Kaskela Law LLC Announces Investigation into Fairness of $16.50 Per Share Select Medical Holdings (SEM) Stockholder Buyout; Affected Investors are Encouraged to Contact the Firm to Protect Their Investment and Legal Rights

NEWTOWN SQUARE, Pa.--(BUSINESS WIRE)--Shareholder litigation law firm Kaskela Law is investigating the fairness of the recently announced buyout of Select Medical Holdings Corp. (NYSE: SEM) (“Select Medical”) shareholders to determine whether the transaction as structured provides investors with a sufficient price for their shares. Click here to register for additional information about this investigation: https://kaskelalaw.com/case/select-medical/ On March 2, 2026, Select Medical announced th...
Back to Newsroom